SCHEMBL12047469

SCHEMBL12047469

CCCCOC(COCCCO)COCC(COCCCO)OCCCO

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 7/20 0.51
LPAR3 Q9UBY5 7/20 0.51
LPAR2 Q9HBW0 4/20 0.51
TSHR P16473 1/20 0.50
USP2 O75604 1/20 0.44
TLR2 O60603 2/20 0.41
HTT P42858 2/20 0.41
MEN1 O00255 1/20 0.41
THRB P10828 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPT P10636 1/20 0.41
LPAR6 P43657 3/20 0.41
LPAR4 Q99677 3/20 0.41
LPAR5 Q9H1C0 3/20 0.41
ALDH1A1 P00352 2/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
DNM1 Q05193 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10028014 1.00 LPAR1 (0.51) LPAR1LPAR3LPAR2TSHRUSP2
SCHEMBL12047466 0.94 LPAR1 (0.47) LPAR1LPAR3LPAR2TSHRUSP2
SCHEMBL12047468 0.94 LPAR1 (0.47) LPAR1LPAR3LPAR2TSHRUSP2
SCHEMBL12047460 0.91 LPAR1 (0.45) LPAR1LPAR3LPAR2TSHRUSP2
SCHEMBL14616861 0.91 HSD17B10 (0.50) LPAR1LPAR3LPAR2TSHRUSP2
SCHEMBL12047464 0.91 LPAR1 (0.45) LPAR1LPAR3LPAR2TSHRUSP2
SCHEMBL12301807 0.91 LPAR1 (0.45) LPAR1LPAR3LPAR2TSHRUSP2
SCHEMBL11314764 0.90 LPAR1 (0.63) LPAR1LPAR3LPAR2USP2TLR2
SCHEMBL12047457 0.90 TSHR (0.43) LPAR1LPAR3LPAR2TSHRUSP2
SCHEMBL8953351 0.89 LPAR1 (0.46) LPAR1LPAR3LPAR2TSHRUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741283-B2 Adenosine deaminase anticancer therapy SIGMA-TAU RARE DISEASES, S.A. (PT) 2014-06-03 US disclosed
US-8367065-B2 Targeted polymeric prodrugs containing multifunctional linkers ENZON PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
US-8268318-B2 Polyalkylene oxides having hindered ester-based biodegradable linkers ENZON PHARMACEUTICALS, INC. (US) 2012-09-18 US disclosed
US-8071741-B2 Stable recombinant adenosine deaminase DEFIANTE FARMACEUTICA, S.A. (PT) 2011-12-06 US disclosed
US-20100273236-A1 RECOMBINANT HOST FOR PRODUCING L-ASPARAGINASE II DEFIANTE FARMACEUTICA, S.A. (PT) 2010-10-28 US disclosed
US-7807436-B2 genetic engineered escherichia comprising chromosome and genetic vectors, that code for hydrolase enzymes; drug/polymer conjugates/ used for treatment of diseases or disorders responsive to asparaginases DEFIANTE FARMACEUTICA, S.A. (PT) 2010-10-05 US disclosed
US-20100233190-A1 TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS ENZON PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed
US-20100203066-A1 POLYMERIC LINKERS CONTAINING PYRIDYL DISULFIDE MOIETIES ENZON PHARMACEUTICALS, INC. (US) 2010-08-12 US disclosed
US-20100056543-A1 POSACONAZOLE POLYMER CONJUGATES AND METHODS OF TREATMENT USING POSACONAZOLE AND POLYMER CONJUGATES THEREOF ENZON PHARMACEUTICALS, INC. (US) 2010-03-04 US disclosed
US-20090232833-A1 POLYALKYLENE OXIDES HAVING HINDERED ESTER-BASED BIODEGRADABLE LINKERS ENZON PHARMACEUTICALS, INC. (US) 2009-09-17 US disclosed
US-20090047270-A1 ENZYMATIC ANTICANCER THERAPY ENZON PHARMACEUTICALS, INC. (US) 2009-02-19 US disclosed
US-20090047271-A1 STABLE RECOMBINANT ADENOSINE DEAMINASE ENZON PHARMACEUTICALS, INC. (US) 2009-02-19 US disclosed
US-20090017004-A1 POLYMERIC DRUG DELIVERY SYSTEMS CONTAINING AN AROMATIC ALLYLIC ACID ENZON PHARMACEUTICALS, INC. (US) 2009-01-15 US disclosed
US-20090016985-A1 POLYMERIC DRUG DELIVERY SYSTEM CONTAINING A MULTI-SUBSTITUTED AROMATIC MOIETY ENZON PHARMACEUTICALS, INC. (US) 2009-01-15 US disclosed
US-20080171013-A1 POSACONAZOLE POLYMER CONJUGATES AND METHODS OF TREATMENT USING POSACONAZOLE AND POLYMER CONJUGATES THEREOF ENZON PHARMACEUTICALS, INC. (US) 2008-07-17 US disclosed
US-20080159964-A1 USE OF ADENOSINE DEAMINASE FOR TREATING PULMONARY DISEASE ENZON PHARMACEUTICALS, INC. (US) 2008-07-03 US disclosed
US-20080063632-A1 RECOMBINANT HOST FOR PRODUCING L-ASPARAGINASE II SIGMA-TAU PHARMA LIMITED (GB) 2008-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100233190-A1 TARGETED POLYMERIC PRODRUGS CONTAINING MULTIFUNCTIONAL LINKERS PAICS, FCGRT, DNPEP LPAR1 1052/4885LPAR3 963/4885LPAR2 763/4885
US-20090047270-A1 ENZYMATIC ANTICANCER THERAPY RNASE1, ADA, DCTD LPAR1 3234/4885LPAR3 3409/4885LPAR2 3064/4885
US-20080159964-A1 USE OF ADENOSINE DEAMINASE FOR TREATING PULMONARY DISEASE ADA, AMPD2, AMPD1 LPAR1 1423/4885LPAR3 1286/4885LPAR2 1455/4885
US-20090017004-A1 POLYMERIC DRUG DELIVERY SYSTEMS CONTAINING AN AROMATIC ALLYLIC ACID AADAC, ACSS2, ANXA6 LPAR1 211/4885LPAR3 177/4885LPAR2 148/4885
US-20090016985-A1 POLYMERIC DRUG DELIVERY SYSTEM CONTAINING A MULTI-SUBSTITUTED AROMATIC MOIETY ABCB1, PAICS, ABCG2 LPAR1 1228/4885LPAR3 572/4885LPAR2 1071/4885
US-20090232833-A1 POLYALKYLENE OXIDES HAVING HINDERED ESTER-BASED BIODEGRADABLE LINKERS CES2, PLOD3, FASN LPAR1 898/4885LPAR3 1016/4885LPAR2 823/4885
US-20080063632-A1 RECOMBINANT HOST FOR PRODUCING L-ASPARAGINASE II ENGASE, LAP3, LNPEP LPAR1 3130/4885LPAR3 3151/4885LPAR2 2867/4885
US-20080171013-A1 POSACONAZOLE POLYMER CONJUGATES AND METHODS OF TREATMENT USING POSACONAZOLE AND POLYMER CONJUGATES THEREOF ALG1, DDOST, B3GAT3 LPAR1 3622/4885LPAR3 2051/4885LPAR2 3823/4885
US-20100056543-A1 POSACONAZOLE POLYMER CONJUGATES AND METHODS OF TREATMENT USING POSACONAZOLE AND POLYMER CONJUGATES THEREOF ALG1, DDOST, B3GAT3 LPAR1 3622/4885LPAR3 2051/4885LPAR2 3823/4885
US-20090047271-A1 STABLE RECOMBINANT ADENOSINE DEAMINASE ADA, CDA, DCTD LPAR1 4227/4885LPAR3 4305/4885LPAR2 4389/4885
US-20100203066-A1 POLYMERIC LINKERS CONTAINING PYRIDYL DISULFIDE MOIETIES P4HB, PRDX4, SCLY LPAR1 2514/4885LPAR3 1286/4885LPAR2 2255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.